Receptor tyrosine kinases as targets for anticancer therapeutics

被引：14

作者：

Carlomagno, F ^{[1
]}

Santoro, M ^{[1
]}

机构：

[1] Univ Naples Federico II, Dipartimento Biol Patol Cellulare & Mol, Ist Endocrinol Oncol Sperimentale, I-80131 Naples, Italy

来源：

CURRENT MEDICINAL CHEMISTRY | 2005年 / 12卷 / 15期

关键词：

kinase; tyrosine; oncogene; germline; thyroid; KIT; MET; RET;

D O I：

10.2174/0929867054367266

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Oncogenic conversion of receptor protein tyrosine kinases (RTK) is a frequent feature of malignant cells. This knowledge has fostered efforts to develop target-specific low molecular weight therapeutics able to obstruct RTK signalling. The clinical efficacy of the ABL- and KIT-inhibitors are paradigmatic of the power of this approach. Here, we focus on small-molecule inhibitors for RTKs involved in human cancer. In particular, we examine the KIT, MET and RET receptors that are targeted by genetic alterations in both sporadic and familial human tumours.

引用

收藏

页码：1773 / 1781

页数：9

相关论文

共 89 条

[1] The GDNF family: Signalling, biological functions and therapeutic value [J].

Airaksinen, MS ;

Saarma, M .

NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) :383-394

[2] RET and NTRK1 proto-oncogenes in human diseases [J].

Albert, L ;

Carniti, C ;

Miranda, C ;

Roccato, E ;

Pierotti, MA .

JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (02) :168-186

[3] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[4] Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells [J].

Armstrong, F ;

Duplantier, MM ;

Trempat, P ;

Hieblot, C ;

Lamant, L ;

Espinos, E ;

Racaud-Sultan, C ;

Allouche, M ;

Campo, E ;

Delsol, G ;

Touriol, C .

ONCOGENE, 2004, 23 (36) :6071-6082

[5] Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].

Armstrong, SA ;

Kung, AL ;

Mabon, ME ;

Silverman, LB ;

Stam, RW ;

Den Boer, ML ;

Pieters, R ;

Kersey, JH ;

Sallan, SE ;

Fletcher, JA ;

Golub, TR ;

Griffin, JD ;

Korsmeyer, SJ .

CANCER CELL, 2003, 3 (02) :173-183

[6] Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? [J].

Arteaga, CL ;

Baselga, J .

CANCER CELL, 2004, 5 (06) :525-531

[7] The biology of stem cell factor and its receptor C-kit [J].

Ashman, LK .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1999, 31 (10) :1037-1051

[8] Mutational analysis of the tyrosine kinome in colorectal cancers [J].

Bardelli, A ;

Parsons, DW ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Saha, S ;

Markowitz, S ;

Willson, JKV ;

Parmigiani, G ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

SCIENCE, 2003, 300 (5621) :949-949

[9] Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth [J].

Bardelli, A ;

Longati, P ;

Gramaglia, D ;

Basilico, C ;

Tamagnone, L ;

Giordano, S ;

Ballinari, D ;

Michieli, P ;

Comoglio, PM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14379-14383

[10]

Bates David, 2003, Curr Opin Investig Drugs, V4, P1468

← 1 2 3 4 5 6 7 8 9 →